PROJECT
About carxall
Our vision is to offer a therapeutic opportunity for patients suffering from R/R T-ALL.
Our approach is unique because it relies on the simultaneous targeting of two safe T-ALL-specific antigens with Chimeric Antigen Receptor (CAR) T-cells.
Our aim is to use our proprietary off-the-shelf platform of Vδ1+ γδ T-cells derived from human cord blood (CORD-GDT cells), a scalable, HLA-independent, allogenic, and safe source of effector T-cells,.
Our purpose is to prove the safety and efficacy of the carxall product and to develop a GMP-compliant manufacturing process for their clinical implementation.
Our intention is to mature the project to be investment-ready within 3 years, thus securing its financial viability to launch a European first-in-human clinical trial.
PROJECT OBJECTIVES
To complete the pre-Clinical Characterization and validation of carxall product
GMP-compliant scale-up manufacturing process of carxall-directed CORD-GDT cells
To develop a business model and a Regulatory pathway to bring these carxall-directed CORD-GDT cells to patients
Work packages
